Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by jjwilsonon Feb 09, 2018 7:55pm
144 Views
Post# 27537135

Prev post messed up formatting

Prev post messed up formattingSorry, formatting messed up for some reason.  Here, I'll try again.

"That being the case, ProMISs' safe being full of IP along with the Plotkin Keys to the Kingdom decoder ProMIS is just in it's beginning stages of finding, developing a host of medical conditions plaguing society." 

 

Every time I read that "keys to the kingdom" it cracks me up. 

 

Anybody reading this board, pay attention to silentrunning because he gets it. 

 

The question that never gets asked; "why does PMN have a Chief Physics Officer, and what does he do?" 

 

Well, here's a patent application from 2010 that was submitted with Dr. Cashman: 
[url=https://www.phas.ubc.ca/~steve/publication/12_574_637_METHODS_AND_SYSTEMS_FOR_PREDICTING_MISFOLDED_PROTEIN_EPITOPES.pdf ]Patent application[/url]

 

You can read it but I guarantee you won't understand a word of it! 

 

Many investors in PMN think they are investing in a drug company - wrong. 

Many investors think the whole thing rides on the success or failure of the AD research - wrong. 

 

What we are actually invested in is two proprietary computational discovery technologies; PROMIS and Collective Coordinates. AD is the furthest along and is the focus of the company at the moment but is only the beginning of what this company will achieve.

Bullboard Posts